A new look at the corporate capability of personalized medicine development in the pharmaceutical industry-Reference-Cited by-同舟云学术

A new look at the corporate capability of personalized medicine development in the pharmaceutical industry

Published:2014-05-28 Issue:1 Volume:45 Page:94-103
ISSN:0033-6807
Container-title:R&D Management
language:en
Short-container-title:R&D Manage

Author:

Haruya Mei¹²,Kano Shingo¹

Affiliation:

1. Bio Intellectual Property Course, Department of Medical Genome Sciences, Graduate School of Frontier Sciences; The University of Tokyo; 5-1-5 Kashiwanoha Kashiwa-shi Chiba 277-8561 Japan

2. GlaxoSmithKline K.K.; Tokyo Japan

Publisher

Wiley

Subject

Management of Technology and Innovation,Strategy and Management,General Business, Management and Accounting,Business and International Management

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/radm.12072/fullpdf

Reference30 articles.

1. The future of drug discovery and development: shifting emphasis towards personalized medicine;Amir-Aslani;Technological Forecasting & Social Change,2010

2. Technological learning, strategic flexibility, and new product development in the pharmaceutical industry;Bierly;IEEE Transactions on Engineering Management,1996

3. Fatigue and physical disability in patients with multiple sclerosis: a structural equation modeling approach;Bol;Journal of Behavioral Medicine,2010

4. The microeconomics of personalized medicine: today's challenge and tomorrow's promise;Davis;Nature Reviews Drug Discovery,2009

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research landscape analysis for quality in Pharma 4.0 era;Technology in Society;2024-03

2. Trends in interorganizational transactions in personalized medicine development;Drug Discovery Today;2019-02

3. Strategic R&D transactions in personalized drug development;Drug Discovery Today;2018-07

4. ResearchWatch;Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing;2014-11